Results 41 to 50 of about 1,482,586 (339)
BMC Cancer, 2018 Background For the expanding population of bladder cancer survivors in Korea, the development of subsequent cancers is a significant concern. Here, we provide the second primary cancer incidence rates and types in Korean patients with bladder cancer ...
Whi-An Kwon +10 more
doaj +1 more source
Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis
BJUI Compass, 2023 Background Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. We performed a systematic review and meta‐analysis to evaluate the prevalence of genomic alterations in NEPC and better understand its molecular features to ...
Junru Chen +6 more
doaj +1 more source
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
Cells, 2022 The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of
Mariia Radaeva +12 more
doaj +1 more source
Talin1 Promotes Prostate Cancer Invasion and Metastasis via AKT Signaling and Anoikis Resistance [PDF]
, 2009 Talin1 is an integrin regulatory protein that mediates integrin interactions with the extracellular matrix (ECM). This study investigated the significance of talin1 in prostate cancer progression to metastasis in vitro and in vivo.
Natasha Kyprianou +2 more
core +1 more source
Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study [PDF]
, 2016 Introduction Current strategies for the management of prostate cancer are inadequate in Australia. We will, in this study, estimate current service needs and project the future needs for prostate cancer patients in Australia.
Clements, M. S. +5 more
core +1 more source
Aggressive prostate cancer is associated with pericyte dysfunction
Molecular Oncology, EarlyView.Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero +11 more
wiley +1 more source
Scientific ReportsFOXA1 is a pioneer transcription factor that is frequently mutated in prostate, breast, bladder, and salivary gland malignancies. Indeed, metastatic castration-resistant prostate cancer (mCRPC) commonly harbour FOXA1 mutations with a prevalence of 35 ...
Kevin J. Tam +13 more
doaj +1 more source
Sexual well-being and diurnal cortisol after prostate cancer treatment. [PDF]
, 2020 Sexual dysfunction and psychological distress are common after prostate cancer. Research has not examined the role of neuroendocrine markers of stress (e.g. cortisol).
Gaffey, Allison E +4 more
core
Death receptor 5 expression is inversely correlated with prostate cancer progression. [PDF]
, 2014 Prostate carcinoma (PCa) is one of the most common cancers in men. Prostate-specific antigen (PSA) has been widely used to predict the outcome of PCa and screening with PSA has resulted in a decline in mortality. However, PSA is not an optimal prognostic
Antonio-Andres, Gabriela +10 more
core +1 more source
Molecular Oncology, EarlyView.The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués +3 more
wiley +1 more source